June 18, 2020   Sweden
Key appointments being made at new diabetes vaccine facility in Umeå
Construction of Diamyd Medical’s new vaccine manufacturing unit in Umeå is now underway, with a number of key roles being actively recruited to help staff the new facility. Newly-appointed site manager Maja Johansson is responsible for establishing the process for the production of GAD, the active substance in the study drug Diamyd®.

“We are convinced that our facility in Umeå will be world-leading and increase Umeå’s growing reputation as a biotech hub,” says Maja Johansson.

Read the press release here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.

Order GAD for preclinical research